Pharmaceuticals
Pharma - API & CRAMS
from 891 today
Initiate at Buy with a PT of INR1,050. Anthem is a high-growth Indian CRDMO with industry-leading manufacturing capabilities, highest EBITDA margin (~40%) and ROCE (~25%) among Indian CRDMOs, and strong growth expected from commercial molecule scale-up and robust late phase projects pipeline.
Ratings and target prices as published by each firm. Each summary condenses that firm's stated view in its own note and is attributed to it; no report text is reproduced.
